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Alzheimer's diseaseAlzheimer's disease (AD) is the most common age-related neurodegenerative disease, affecting an estimated
5.3 million people in the United States. While many factors likely contribute to AD progression, it is widely
accepted that AD is driven by the accumulation of β-amyloid (Aβ), a small, ﬁbrillogenic peptide generated by
the sequential proteolysis of the amyloid precursor protein by the β- and γ-secretases. Though the underlying
causes of Aβ accumulation in sporadic AD are myriad, it is clear that lifestyle and overall health play a signiﬁcant
role. The adipocyte-derived hormone leptin has varied systemic affects, including neuropeptide release and
neuroprotection. A recent study by Lieb et al. (2009) showed that individuals with low plasma leptin levels
are at greater risk of developing AD, through unknown mechanisms. In this report, we show that plasma leptin
is a strong negative predictor of Aβ levels in themouse brain, supporting a protective role for the hormone in AD
onset. We also show that the inhibition of Aβ accumulation is due to the downregulation of transcription of the
γ-secretase components. On the other hand, β-secretase expression is either unchanged (BACE1) or increased
(BACE2). Finally, we show that only presenilin 1 (PS1) is negatively correlated with plasma leptin at the protein
level (pb0.0001). These data are intriguing andmay highlight a role for leptin in regulating the onset of amyloid
pathology and AD.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD), the most common age-related neurode-
generative disease, is a continually growing socio-economic burden
in industrialized nations, such as the United States, where the median
life expectancy now tops 78 years. While a small number of AD
cases are familial, due to well-characterized mutations in the amyloid
precursor protein (APP) and presenilin (PS1 and PS2) [1], the majority
are sporadic, with no clear etiology.
It is nowwidely accepted that ADpathology is driven, at least initially,
by the accumulation of β-amyloid (Aβ), a small ﬁbrillogenic peptide
cleaved from the larger, membrane-bound APP [2]. This peptide rapidly
oligomerizes, stimulating many downstream events and ultimately
leading to neurodegeneration [3]. The production of Aβ is achieved by
the sequential proteolysis of APP by the β- and γ-Secretases — both of
which have been explored as targets for AD therapeutics. γ-secretase is
a multimeric enzyme complex that completes the conversion of APP
C-terminal fragments to Aβ peptides through the actions of its catalyticrown 211, Lexington, KY 40536,
phy).
rights reserved.subunit, presenilin. Transcriptional, translational, and post-translational
control of β- and γ-secretase expression and assembly is tightly
controlled [4–8]. Aβ accumulation in sporadic AD arises from an imbal-
ance between its production and degradation, though the processes
underlying this imbalance are unclear and likely intertwined. It is
well-documented that lifestyle and overall health impact disease devel-
opment and progression, however [9–15].
Leptin is a hormone released from adipose tissue that regulates
satiety and energy balance via hypothalamic signaling in the brain
and subsequent neuropeptide release [16]. Though the effects on
other areas of the brain are less clear, leptin has been reported to
improve long-term potentiation in neurons and to be neuroprotective
[8,17,18], likely via the potentiation of pro-growth and anti-apoptotic
signals [19–22]. In addition, leptin has been shown to negatively
regulate Aβ production and tau phosphorylation in neuronal cell lines
and primary neurons [23,24]. Intriguingly, a recent paper reported
that low plasma leptin is associated with increased AD risk in elderly
humans [25], through unknown mechanisms.
In this report, we show that plasma leptin is strongly and negatively
correlated with brain Aβ levels and presenilin 1 (PS1) expression in
mice. In addition, leptin increases APP C-terminal fragment (CTF) and
Aβ accumulation and reduces mRNA expression of γ-secretase compo-
nents in human neuroglioma cells.
Table 1
qPCR gene-speciﬁc primers.
Target Gene Direction Sequence
PS1 Forward
Reverse
5′-AAATGGGTGCTTTGTGGTCTCTGC-3′
5′-CAGGCTGATGGCTGTTTGTGTGTT-3′
PS2 Forward
Reverse
5′-ATGGACAGCTCATCTACACGCCAT-3′
5′-AGAGCACCACCAAGAAGATGGTCA-3′
PEN2 Forward
Reverse
5′-TCTCGCGCAAACGTCCATAACTGA-3′
5′-AATGGACACTCGCTCCAGGTTCAT-3′
Nicastrin Forward
Reverse
5′-AGTGCCCAAATGATGGGTTTGGTG-3′
5′-TCATAAGCCAAACCATTGCCCAGC-3′
APH1A Forward
Reverse
5′-ATCCGCCAGATGGCCTATGTTTCT-3′
5′-AGCAGGATAATGGCTGCTGTCAGA-3′
APH1B Forward
Reverser
5′-TTATGTCTTCACCATCGCCACCGA-3′
5′-TTGCCATGAACCAAACAAGGGACG-3′
BACE1 Forward
Reverse
5′-ATGTTGCCACTCTGCCTCATGGTA-3′
5′-TGAGCAGGGAGATGTCATCAGCAA-3′
BACE2 Forward
Reverse
5′-TGAGGACCTTGTCACCATCCCAAA-3′
5′-TGGCCAAAGCAGCATAAGCAAGTC-3′
18S rRNA Forward
Reverse
5′-TTAGAGTGTTCAAAGCAGGCCCGA-3′
5′-TTGGCAAATGCTTTCGCTCTGGTC-3′
β-Actin Forward
Reverse
5′-ACCAACTGGGACGACATGGAGAAA-3′
5′-TAGCACAGCCTGGATAGCAACGTA-3′
GAPDH Forward
Reverse
5′-TCGACAGTCAGCCGCATCTTCTTT-3′
5′-ACCAAATCCGTTGACTCCGACCTT-3′
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2.1. Animals
For leptin measurements, 1–2 month old APPΔNLh×PS1P264L
knock-in mice (wild-type, n=37; heterozygous, n=49; homozygous,
n=21; total, N=107) [26]were fed a control (20% fat, n=46),western
(40% fat, n=14) or ketogenic (80% fat, n=47) diet (Research Diets) ad
libitum for 1 month. Mice were split approximately equally by gender
(M: n=52; F: n=55). Animals were euthanized by CO2 asphyxiation
followed by decapitation, and the tissues and blood collected. In an
independent set of experiments, 6 (n=19) and 18 (n=18) month
old male APPΔNLh×PS1P264L knock-in mice (homozygous, n=18;
wild-type, n=19; total, N=37) were used for body composition anal-
yses, as well as serum analyses. Mice were euthanized by isoﬂurane
anesthesia, followed by cardiac puncture and decapitation.
2.2. Plasma and serum measurements
Plasma was obtained from whole blood by low speed centrifuga-
tion (1500 ×g, 10 min). Leptin was measured in plasma using a
commercially-available ELISA (Millipore, Billerica; MA), according
to manufacturer's instructions. Serum was obtained from whole
blood by allowing it to clot at 4 °C overnight followed by centrifugation
(3000 ×g, 30 min). Serumwas collected andeither analyzed immediately
or aliquoted and stored at -80 °C. Levels of total cholesterol, HDL
cholesterol, LDL cholesterol, triglycerides, and non-esteriﬁed fatty acids
(NEFA) in sera weremeasured colorimetrically using commercially avail-
able kits (Wako Chemicals; Richmond, VA). Serum adiponectin, leptin,
and insulin levels were all evaluated by ELISA in accordance with the
manufacturer's assay protocol (R&D Systems; Minneapolis, MN for
adiponectin; R&D Systems for leptin; and Crystal Chem Inc.; Downers
Grove IL for insulin). To measure total pools of adiponectin, serum sam-
ples were ﬁrst denatured (boiled in SDS buffer for 5 min) to break
down large complexes.
2.3. Cell culture
H4 neuroglioma cells stably overexpressing APPΔNLh were grown in
Opti-MEM (Invitrogen; Carlsbad, CA) with 10% fetal bovine serum
(HyClone; Logan, UT) and 1% penicillin-streptomycin, supplemented
with hygromycin (200 μg/mL) as described [27,28]. H4 wild-type cells
were grown in the absence of hygromycin. SH-SY5Y neuroblastoma
cells were grown in Dulbecco's Modiﬁed Eagle's Medium (DMEM)
supplemented with 10% fetal bovine serum and 1% penicillin-
streptomycin. Upon reaching conﬂuence, serum was removed and the
cells were treated with recombinant human leptin (Sigma-Aldrich; St.
Louis, MO) for 24 h. H4-conditioned media, containing Aβ, were
collected, and the cells were lysed in RIPA buffer (1% Triton X-100/0.5%
sodium deoxycholate/ 0.1% SDS/50 mM Tris/150 mM NaCl+Protease
Inhibitor Cocktail (Amresco; Solon, OH), pH=8.0). Two independent
experiments were performed.
2.4. Aβ ELISA
Frozen brain tissue was homogenized in 2% SDS with Complete
Protease Inhibitor Cocktail using an AHS200 PowerMax homogenizer.
Insoluble material was removed by centrifugation (20,800×g,
30 min., 14 °C) and the supernatants frozen until use. Total Aβ was
measured by sandwich ELISA as previously described [27]. Brieﬂy,
SDS extracts were diluted in AC buffer (0.2 M sodium phosphate
(pH 7), 0.4 M NaCl, 2 mM EDTA, 0.4% Block Ace (Serotec; Raleigh,
NC), 0.4% BSA, 0.05% CHAPS, 0.05% NaN3) for analysis. A standard
curve was prepared from recombinant human Aβ1-42 diluted in AC
buffer. Standards and samples were measured at least in duplicate.
384-well plates (Immulon 4HBX; Thermo Scientiﬁc; Waltham, MA)were coated with 0.5 μg Ab9/well (against human Aβ1-16) and blocked
with Synblock (Serotec) according to the manufacturer's instructions.
After incubation with the samples and standards, Aβ was detected
with biotinylated-4G8 (against Aβ17-24; Covance; Princeton, NJ),
followed by incubation with 0.1 μg/mL NeutrAvidin-HRP (Pierce
Technologies; Rockford, IL). The plate was developed with
3′,3′,5′,5′-tetramethylbenzidine (TMB; Kirkeguard and Perry
Laboratories; Gaithersburg, MD) and the reaction stopped with 6%
o-phosphoric acid. The absorbance at 450 nm was measured with a
BioTek multiwell plate reader. H4 cell culture media was assayed for
Aβ40 using a commercially-available ELISA kit (BioSource; Carlsbad,
CA). The Aβ42 levels in the media were below detection limits. Data
were averaged over 4-5 replicates.
2.5. qRT-PCR
RNA was extracted from leptin-treated wild-type H4 or SH-SY5Y
cells using TRIzol® (Invitrogen). RNA from the SH-SY5Y cells was
subsequently puriﬁed by RNeasy columns (Qiagen; Valencia, CA).
Expression of the γ-secretase components was determined by two-
step qRT-PCR, using iScript (BioRad; Hercules, CA) reverse transcrip-
tion, followed by qPCRwith PerfeCTa FastMix™ (Quanta; Gaithersburg,
MD). The geometric mean of the CT values for 18S rRNA, β-actin, and
GAPDH was used as an internal control to calculate and compare rela-
tive expression (2−ΔΔCT). Gene speciﬁc primer sets were obtained
from IDT (Coralville, IA; Table 1). All measurements were performed
in triplicate. Data was averaged from 2 to 3 independent experiments.
2.6. Immunoblots
Protein levels of APP and the γ-secretase components were deter-
mined by Western or spot blot, using antibodies directed against
APP (CT20) [27], PS1 (Calbiochem; Gibbstown, NJ), PEN2 (Abcam;
Cambridge, MA), or APH1A (Pierce; Rockford, IL). The antibody
directed at the C-terminus of nicastrin was a kind gift from Dr. Paul
Fraser [29]. Immunoreactive bands were visualized with Super Signal
West Dura chemiluminescence HRP substrate (Pierce) and exposed to
ﬁlm. Densitometric analyses were performed using Scion Image or
Image J. Expression of the γ-secretase components was standardized
to β-actin (Sigma-Aldrich) expression in the same lane or spot,
respectively. Spot blot measurements were performed in triplicate.
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subset of mice (N=65 for PS1, PEN2, and APH1; N=16 for nicastrin).
2.7. Body Composition Analysis
Body composition was measured using a Bruker minispec LF90
time domain NMR analyzer (Bruker Optics; Billerica, MA) as de-
scribed previously [30].
2.7.1. Statistics
Data were analyzed by linear regression using SPSS® for Windows
(Hewlett Packard; Houston, TX). Correlationswere analyzed as Pearson
product moment for parametric (plasma leptin, brain Aβ) or Spearman
rank order for nonparametric (immunoblot) variables. RT-PCR data
were analyzed using a Mann-Whitney U nonparametric ANOVA. Aβ
secretion values were analyzed by parametric ANOVA followed by
Dunnett's test for multiple comparisons to a control group. The effect
of body weight, fat, and muscle on Aβ was analyzed by parametric
ANOVA. The effect of leptin administration on plasma leptin was
analyzed by a one-tailed, nonparametric, Mann–Whitney test. When
necessary,manual adjustment formultiple comparisonswas performed
using the Holm–Bonferroni procedure. All micewere analyzed together
as a single population to maximize power.
3. Results
3.1. Plasma leptin and Aβ
Wemade a striking observation during a study examining the effect
of high fat diets on Aβ generation in the APPΔNLh×PS1P264L knock-in
mouse model of AD: plasma leptin was strongly and negatively corre-
lated with total brain Aβ (Fig. 1; R2=0.26, pb0.0001, N=105). This
data includes young (2–3 months old) mice of different genotypes,
with one or two copies of mutant APP and/or PS1, as well as wild-type
controls. In an effort to remove the contribution of endogenous rodent
Aβ, we also performed the correlation with the exclusion of animals
containing only wild-type rodent APP. This change modestly improved
the strength of the observed correlation (R2=0.35, pb0.0001, N=69).
These data indicate that leptin has a protective effect on some aspect
of Aβ metabolism. While the diets used in this study signiﬁcantly
increased plasma leptin levels (p=0.02), there was no effect on brain
Aβ (p=0.66), supporting the conclusion that the correlation observed
is driven by plasma leptin and not the variation in diet.Fig. 1. Plasma leptin negatively correlates with brain Aβ. There was a strong negative cor-
relation between plasma leptin and brain Aβ in young (2–3 month-old) APPΔNLh×PS1P264L
knock-in mice (N=105; pb0.0001).Leptin is an adipose-derived hormone that is important for satiety
and energy balance and expenditure, including insulin sensitivity and
fatty acid uptake into muscle and liver [31,32]. In addition, circulating
levels of leptin are directly inﬂuenced by weight and fat mass, which
also determine the levels of other adipokines, such as adiponectin. In
order to determine whether the observed correlation between plas-
ma leptin and brain Aβ was driven by leptin itself, or by other factors
either affecting or affected by leptin, we looked at a separate, small
(N=37) cohort of middle aged (6 months) and older (18 months)
APP×PS1 knock-in and wild-type mice that were maintained on a
control diet (Table 2). The APP×PS1 knock-in mice have signiﬁcantly
elevated Aβ (pb0.0005; consistent with previous reports [26]),
triglycerides (pb0.03), non-esteriﬁed fatty acids (NEFA; p=0.002),
total cholesterol (pb0.0005), high-density lipoprotein (HDL;
p=0.025), and low-density lipoprotein (LDL; pb0.0005). Conversely,
APP×PS1 mice have signiﬁcantly reduced serum leptin (p=0.04)
and adiponectin (p=0.01), compared with wild-type controls. There
was an age-dependent increase in weight (p=0.001), muscle mass
(pb0.0005), free ﬂuids (pb0.0005), cholesterol (p=0.003), serum
insulin (p=0.004), and Aβ (pb0.0005). There was an age-dependent
decrease in triglycerides (p=0.009), NEFA (pb0.0005), and serum
adiponectin (p=0.015).
We next examined whether any of these observed effects were
associated with changes in brain Aβ. Weight, fat mass, and muscle
mass did not signiﬁcantly correlate with brain Aβ (p>0.43 in all
cases), supporting the hypothesis that body composition is not
non-speciﬁcally related to the level of brain Aβ. Free ﬂuid content
was marginally signiﬁcant (p=0.05), though the reason for this is
unclear. Plasma lipids in the form of triglycerides and NEFA were
also not signiﬁcantly correlated (p>0.5) with Aβ. Similarly, plasma
insulin was not correlated with brain Aβ (p=0.21). Consistent with
previous reports, cholesterol was strongly correlated with Aβ, partic-
ularly total cholesterol and LDL (pb0.0005 for both). These data
support a speciﬁc role for leptin as a regulator of Aβ in the brain.
3.2. Effect of leptin on cells in culture
In order to determine if leptin has a direct effect on Aβ production
in neural cells, we treated APPΔNLh-overexpressing H4 neuroglioma
cells with leptin and measured the effect on APP processing and Aβ
generation. There was a dose-dependent decrease in the amount of
Aβ generated in cells treated with leptin in the physiological range
observed in mice (10–50 ng/mL): there was a signiﬁcant reduction in
cells treated with 50 ng/mL leptin (Fig. 2A; p=0.024). This was con-
comitant with accumulation of APP α- and β-C-terminal fragments
(Fig. 2B). These two events are hallmarks of reduced γ-secretaseTable 2
Effect of APP/PS1 mutations.
Wild-type APP/PS1
6 months 18 months 6 months 18 months
Weight (g)b 38±1.8 47.4±1.9 40.8±1.9 45.2±1.9
Fat (g) 7.85±1.37 10.1±1.45 6.43±1.45 9.82±1.45
Muscle (g)b 25.91±0.74 31.37±0.78 28.67±0.78 30.01±0.78
Free ﬂuids (g)b 1.14±0.19 1.99±0.2 1.2±0.2 2.02±0.2
Triglycerides (mg/dL)a,b 38.1±4.6 25.5±4.8 49.3±4.6 36±5
NEFA (mEq/dL)a,b,c 1.42±0.09 1.04±0.1 1.76±0.09 1.33±0.1
Cholesterol (mg/dL)a,b 70.9±7.8 91.6±8.1 98.8±7.8 129.7±8.5
HDL (mg/dL)a 69±7 70.7±7.3 86.2±7 87.3±7.7
LDL (mg/dL)a 15±3.7 17.4±3.8 25.4±3.7 35.8±4
Insulin (ng/mL)b 6.6±2.1 14.6±2.3 5.8±2.1 11.1±2.3
Leptin (ng/mL)a 3.67±1.52 7.59±1.52 1.36±1.52 3.17±1.63
Adiponectin (ng/mL)a,b 787±44 569±46 566±44 550±49
Total Aβ (pM)a,b 1312±76 3834±70 1732±79 81936±9972
a Signiﬁcant effect of genotype (p≤0.05).
b Signiﬁcant effect of age (p≤0.05).
c NEFA=non-esteriﬁed fatty acids.
Fig. 3. Leptin treatment reduces mRNA levels of γ-secretase components in cell culture.
mRNA expression of the γ-secretase components PS1, PEN2, nicastrin, and APH1 were
decreased after leptin treatment in wild-type neuronal tissue culture cells. On the
contrary, there was an overall increase in the expression of BACE2 (p=0.014), one
of the β-secretase enzymes. There was no change in PS2 or BACE1 mRNA expression
(p>0.12). The data are an average of 2–3 independent experiments.
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led us to ask the question of how leptin affects this process.
γ-Secretase is a multimeric complex, whose four main components
(presenilin (PS), nicastrin, PEN2, and APH1) are individually and coordi-
nately regulated, both transcriptionally and post-translationally [4].
Because leptin binds to cell surface receptors, stimulating intracellular
signaling and transcriptional regulation [34], we examined the possibility
that leptin regulates transcription of γ-secretase components bymeasur-
ing mRNA expression by quantitative RT-PCR after leptin treatment of
wild-type H4 cells. We found that leptin treatment reduced expression
ofmany of the components of the enzyme complex (PS1, PEN2, nicastrin,
and APH1B) by ~30–50% (Fig. 3; pb03 in all cases). Expression of PS2,
another presenilin isoform, was unchanged (p=0.4). We saw the same
effect in SH-SY5Y cells, a human neuroblastoma cell line (data not
shown). Finally, because recent reports have postulated that leptin regu-
lates Aβ via β-secretase regulation [23], we measured the effect of leptin
treatment on BACE1 and BACE2 mRNA expression in H4 cells. Leptin
treatment had no effect on the transcription of BACE1 (Fig. 3; p=0.3),
but led to an increase in the expression of BACE2 (p=0.004). While
this is a potentially interesting result, an increase in BACE2 expression
due to plasma leptin levels would not account for the decrease in Aβ
observed in cells treated with leptin. Together, these data indicate
that leptin inhibits expression of γ-secretase components, leading to a
reduction of Aβ.
3.3. Effect of leptin on γ-secretase expression in the brain
We next wanted to determine if leptin also affects the γ-secretase
components at the protein level, focusing on those components that
were affected at the mRNA level. PS1 protein expression was signiﬁ-
cantly, inversely correlated with plasma leptin (Fig. 4A; pb0.0001),
demonstrating that this regulation occurs in vivo. Brain expression
of PEN2 (pb0.73) and APH1A (pb0.59) were not signiﬁcantly corre-
lated with plasma leptin, suggesting that leptin does not directly
affect expression of these molecules at the protein level. In addition,
PS1 expression was positively correlated with brain Aβ (Fig. 4B;
pb0.004), supporting a causative effect on amyloid accumulation.
We also examined a subset of mouse brain samples by Western
blot. Interestingly, nicastrin displayed a size shift to a lower molecular
weight (Fig. 4C) in mice with higher plasma leptin levels (Fig. 4D;
p=0.03). This change is consistent with the accumulation of the
immature, partially deglycosylated form of nicastrin [29], which
requires presenilin for its maturation through the endoplasmic
reticulum. Similarly, treatment of H4 cells with exogenous leptinFig. 2. Leptin treatment inhibits Aβ production in cell culture. Leptin reduced the Aβ
concentration in conditioned media from APPΔNLh-overexpressing H4 neuroglioma
cells after 24 h of treatment (A; *=pb0.05), concomitant with accumulation of APP
C-terminal fragments (CTFα and β: B), indicative of reduced γ-secretase activity. Two
independent experiments were performed. A is an average of the two experiments, while
B is a representative immunoblot of the results.induced a shift to the immature form of nicastrin (Fig. 4E), though
this change did not reach signiﬁcance (Fig. 4F; p>0.09 for all pairwise
comparisons). Together, these ﬁndings show that leptin is an impor-
tant regulator of APP processing and Aβ production through its regu-
lation of PS1 transcription. Finally, we performed a validation analysis
in a randomly-selected subset of ~50% of the animals. This yielded
identical results for the relationships between plasma leptin and Aβ
(R2=0.33, pb0.0001, N=57), plasma leptin and PS1 (R2=0.21,
pb0.0001, N=51), and PS1 and Aβ (R2=0.16, pb0.004, N=52).
4. Discussion
The data presented herein support a role for the circulating hormone
leptin in the regulation of γ-secretase and, hence, Aβ accumulation in the
brain. Our data indicate that leptin transcriptionally regulates PS1 mRNA
expression in neuronal cells (Fig. 3), thereby reducing PS1 protein levels
in the brain (Fig. 4A). This regulation appears to be speciﬁc to the PS1 iso-
form of presenilin as there was no change in PS2 expression upon addi-
tion of leptin to neuronal cells (Fig. 3). These changes likely impact
catalytic activity of the γ-secretase complex. Indeed, it has been demon-
strated previously that alterations in PS1 protein levels impact formation
of stable γ-secretase complexes, ultimately affecting expression and
modiﬁcation of the other components, which in turn regulates
γ-secretase activity [4]. Consistent with these reports, we also observed
a decrease inmRNAexpression of otherγ-secretase components, includ-
ing nicastrin, PEN2, and APH1 (Fig. 3), though these changes did not ex-
tend to the protein level. In addition, we have observed a
leptin-dependent accumulation of immature, partially-glycosylated
nicastrin, both in cell culture and mouse brain extracts (Fig. 4C,E), indi-
cating that levels of active protein may be affected, even if total protein
is not. Based on this data, it is likely that the changes in PEN2, nicastrin,
and APH1 mRNA levels are a result of PS1 downregulation and not a di-
rect result of leptin treatment Another possibility is that leptin
downregulates the gene expression of the γ-secretase components, but
that these changes only affect the steady-state protein level of PS1.
Our ﬁndings highlight a potential role for leptin in the etiology
of AD. These results have profound implications on the AD ﬁeld.
Currently, there are no widely accepted peripheral biomarkers of AD
[35,36], making pre-diagnosis difﬁcult. The current standard of cogni-
tive testing relies on the detection of existing memory deﬁcits, and
may preclude advance preventative strategies. Plasma leptin could
Fig. 4. Plasma leptin negatively correlates with PS1 expression in brain. Plasma leptinwas strongly and negatively correlatedwith brain PS1 protein levels (A: N=65; pb0.0001), but not
other γ-secretase components (not shown: N=65; PEN2, pb0.727; APH1A, pb0.591). The amount of PS1 protein was positively correlated with brain Aβ (B: N=65; pb0.004). Brain
nicastrin (C) displayed a shift to a smaller molecular weight with increasing plasma leptin concentrations (D: N=16; p=0.03), indicating accumulation of an immature form of the
protein. Similarly, leptin treatment of H4 cells led to accumulation of the immature form of nicastrin (E), though the change was not signiﬁcant (F: N=1−; p=0.31).
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[25,37], demonstrating that assessment of plasma leptin inmiddle-aged
and elderly individuals holds some promise in this regard. In addition,
leptin provides a novel target for prevention, through replacement
therapy, as well as therapeutic treatment of AD.
Leptin has been studied extensively in the context of obesity-linked
diabetes, a disease that confers a signiﬁcantly elevated risk for AD
through unknown mechanisms [9,38,39]. Because leptin circulates at
levels proportional to the amount of adipose tissue, obese individuals
have signiﬁcantly elevated plasma leptin [40]. Under normal circum-
stances, high levels of leptin should be neuroprotective. However,
persistent hyperleptinemia renders the hypothalamus, and likely
other areas of the brain, incapable of responding to plasma leptin — a
consequence known as leptin resistance [16]. Therefore, diabetic
patients are part of a subclass of AD patients that may require unique
preventatives and/or therapeutics. Discerning the signaling pathways
involved in leptin-mediated PS1 and Aβ regulationmay provide a target
for these strategies. To this end, an animal model with features of both
diseases may help to shed light on these mechanisms.
Finally, another interesting question to address in the future will
be the additional ramiﬁcation(s) of leptin-mediated PS1 regulation.
In other words, why is PS1 a target of leptin signaling in non-
pathological conditions? While the answer to this question is still
unclear, one intriguing possibility is the recently elucidated role for PS1
in autophagy [41,42]. A hormone, such as leptin, that controls cellular en-
ergy homeostasis would likely play a role in starvation-induced protein
turnover, and control of presenilin expression is oneway to achieve that.5. Conclusions
In conclusion, plasma leptin directly controls PS1 expression via tran-
scriptional regulation. Downregulation of PS1 subsequently decreases
expression of the other γ-secretase components, thereby reducing
γ-secretase activity and Aβ generation. Low plasma leptinmay therefore
contribute to theonset of AD andmayprovide a novel avenue of research
into the mechanisms underlying the disease, as well as biomarker and
prevention research.Acknowledgements
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